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Background: Fibrin sealants are currently used in a variety of surgical and endoscopic settings to improve time to
haemostasis, reduce blood loss and complications. However, the application of sealants (composed of two essential
components: fibrinogen and thrombin) is not without difficulties. These sealants are normally applied to the resected area
using dual-chamber delivery systems. Administration of these substances with different viscosities and diverse flow rates
through a long catheter means that a certain amount of force needs to be applied and clot formation and clogging at
the distal end of the catheter can occur.
Methods: We designed a novel dual-lumen catheter to facilitate the optimal application of fibrin sealant after diagnostic
and therapeutic percutaneous procedures and assessed the efficacy and tolerability of this dual-lumen kit when used in a
model of hepatic fine needle aspiration (FNA) biopsy and radiofrequency ablation (RFA) in an in vivo, preclinical porcine
study.
Results: The experimental was performed on nine pigs (mean body weight 85 ± 7 kg) and with the exception of one
pig, all animals survived in good conditions until the day of hepatectomy and euthanasia. The premature death of this
animal was in the veterinarian’s judgment caused by a common, non-infective disease. In all nine pigs, bleeding was
stopped within 3 minutes of the application of the fibrin sealant and no cases of recurrent bleeding occurred.
Conclusions: The new dual aspect catheter increased ease of delivery of the sealant and FNA liver biopsy and RFA
procedures were successfully and safely performed.
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Hepatocellular carcinoma (HCC) is one of the most com-
mon human solid malignancies worldwide [1,2]. The liver
is also a frequent site of metastases from non-hepatic
malignancies [2]. Surgical resection of the tumour is an
effective treatment. However, less than 10–30% of primary
and secondary hepatic malignancies are resectable due to
tumour number/location, and the risk of liver failure after
partial hepatectomy [3,4]. A number of cytodestructive
treatments are available for patients with unresectable
hepatic tumours including thermal ablation techniques
such as radiofrequency ablation (RFA) which has been* Correspondence: f.izzo@istitutotumori.na.it
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unless otherwise stated.increasingly used in recent years [5,6]. RFA is not without
complications, which range from 6.3–9.5% according to
current estimates [2,7-9]. Frequently reported compli-
cations associated with percutaneous RFA include ab-
dominal haemorrhage, bile leakage, biloma formation,
hepatic abscesses, and neoplastic seeding [2,7-9]. Abdom-
inal bleeding and neoplastic seeding are also associated with
percutaneous diagnostic hepatic procedures as highlighted
in a recent review involving patients who underwent fine
needle aspiration (FNA) liver biopsy [10].
Control of intraoperative haemorrhage is particularly
difficult when the site is poorly accessible, in the presence
of altered coagulation parameters and in patients with
congenital or acquired bleeding disorders. Parenchymal
organs, such as the liver, pose additional problems due to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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niques have been developed over the past decades to en-
sure haemostasis during liver resection, including selective
suture, electrocautery, argon beam coagulation, and vari-
ous manoeuvers [11,12]. Haemostatic agents for topical
application have also been developed as additional mea-
sures to promote haemostasis and tissue sealing [13].
Among these, fibrin sealants also referred to as fibrin
glues, have been used in a variety of surgical and endo-
scopic settings [14-16]. Fibrin sealants are composed of
two essential components, fibrinogen and thrombin,
plus other ingredients including factor XIII (for fibrin
cross-linking), calcium chloride and aprotinin (for pre-
vention of clot fibrinolysis) [17]. Fibrin sealants pro-
mote haemostasis by mimicking the final stage of the
blood coagulation cascade. Clot formation is therefore
possible independently of the patient’s coagulation
status or antithrombotic medication.
Fibrin sealant preparations are currently commercially
available and are successfully used in clinical practice
worldwide. However certain limitations in application
techniques have been observed. They are normally
applied to the resected area using dual-chamber delivery
systems, with one chamber containing fibrinogen and
the other thrombin. Application of fibrin sealants in
open surgery is relatively straight-forward [17], but deliv-
ery through an injection catheter in endoscopic proce-
dures is more problematic as considerable force may be
required to inject the highly viscous fibrinogen compo-
nent through a long catheter [14,18,19]. In addition,
because the two sealant components have different
viscosities and consequently diverse flow rates through
the catheter, inappropriate clot formation at the distal
end of the catheter and clogging can occur.
We describe here a novel type of dual-lumen catheter
designed to facilitate the optimal application of fibrin
sealant after diagnostic and therapeutic percutaneous
procedures. The main objectives of this in vivo, preclin-
ical study were to determine the ease-of-use and/or limi-
tations of this new catheter and to test the efficacy and
safety of the haemostatic treatment when applied via the




The dual-lumen catheter was designed for the application
of Tisseel® (Baxter) and other fibrin sealants following
percutaneous liver procedures including FNA biopsy and
RFA. Fibrinogen and thrombin solutions have different
viscosities and therefore different flow rates through the
catheter lumen which mean they are not delivered simul-
taneously and in equal amounts to the injury site leading
to inadequate sealant application and clot formation. Theaim was to design a catheter through which the two com-
ponents would flow at similar rates and would be deliv-
ered simultaneously and in equal amounts at the site of
injury thus reducing the time and force necessary to inject
the sealant.
The first step was to modify the lumen of the catheter
based on the density and viscosity of each solution.
Using Poiseuille’s law it established that the optimal ratio
between the surface of the lumen cross section contain-
ing the fibrinogen solution (the more viscous solution)
and that of the lumen containing the thrombin solution
(less viscous) should be greater than the square root of
the ratio of the viscosities of both solutions. The dual-
lumen catheter of in the present study was then manu-
factured based on these dimensions.
Kit and procedure for catheter use
The kit used in the present study consisted of a 14G
introducer, a 15G coaxial dual-lumen catheter, and a
needle (Figure 1a,b,c). The introducer (Grimalind® L25)
and catheter (20 cm long) were graduated, of the same
length (200 mm) and made of radiopaque material (30%
barium sulfate). The catheter had a steel core, a sharp
and removable tip that was slightly longer than the
introducer (210 mm) and a Luer-Lock connection. The
needle had an oblique tip to allow easy penetration of
the tissue. The catheter composed of Grilfex® ELG 6260
(PEBA) — a radiopaque and semi-rigid material — has
two chambers one for each sealant component and has
now been granted and an Italian patent (0001395842) and
an international patent is pending (PCT/IT2010/000241)
(Figure 2). To perform a biopsy/percutaneous therapeutic
procedure, the appropriate introducer is positioned using
US, CT or MR imaging guidance (Figure 3). After remov-
ing the core of the introducer, the appropriate needle for
the procedure is inserted and when treatment is com-
pleted the needle is removed and the coaxial, dual-lumen
catheter for sealant application is inserted. The sealant is
injected into the biopsied or ablated area, along the intro-
ducer track, while the introducer is carefully removed.
Animals and treatments
The experimental procedure was performed on Large
White pigs. Each animal received an identification num-
ber and data on each animal were recorded in a data-
base, under the supervision of the principal investigator.
The health status of the animals, including the results of
laboratory tests, was assessed by a veterinary. The study
was approved by the local Ethics Committee for animal
experimentation.
The pigs were randomly assigned to three groups, based
on the length of follow-up after the intervention. Pigs in
Group 1 had no follow-up (sub-acute outcome), pigs in
Group 2 were followed for 2 weeks, (2-week outcome)
Figure 1 Design of the dual-lumen catheter. (a) introducer (14G),
coaxial dual-lumen catheter (15G) and needle (b) longitudinal section
showing introducer, catheter and needle (c) transverse section showing
diameters of lumen.
Figure 2 Patented minimally invasive percutaneous
procedure-kit (MIPP-Kit).
Figure 3 Needle being inserted in liver parenchyma.
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animals underwent laparoscopic examination under gen-
eral anaesthesia. Three liver FNAs with 18G needle fromone liver lobe and three RFA with 14G needle electrode,
from Boston Scientific (maximum 250 watts) at three dis-
tinct liver lobes were performed on each animal (Figure 4).
After assessment of bleeding severity, Tisseel® (10 ml)
(Baxter) was applied via the novel catheter in the treated
areas and along the path of the needle used (Figure 4). Pigs
in Group 1 underwent total hepatectomy and were eutha-
nized 24 hours after the intervention, while pigs in Groups
2 and 3 were hepatectomized and euthanized 2 and 4
weeks after the intervention, respectively.
Assessments
The primary efficacy measure was achievement of haemo-
stasis within 3 minutes of application of fibrin sealant. If
bleeding persisted after 3 minutes the surgeon was free to
use any other technique of his/her preference to control
the haemorrhage. At the end of the procedure but before
suture, sites treated with fibrin sealant were checked again
to make sure they were not bleeding. Throughout the
Figure 4 Radiofrequency ablation procedure: (a) radio frequency electrode, (b) electrode inserted in the liver parenchymal, (c) surface
of the liver parenchyma where electrode was inserted, (d) section of the liver parenchymal showing necrosis and Tisseel.
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complications and side-effects described as mild/moderate
or severe, and as treatment related/unrelated to treatment
according to the investigator’s judgment.
Coagulation parameters were monitored before sur-
gery, before and 24 hours after anaesthesia and at the
end of the follow-up before total hepatectomy. Blood
analyses were carried out on all animals in Groups 2 and
3 each week until total hepatectomy. Removed livers
were assessed by macroscopic and microscopic analysis
to detect any changes caused by FNA, RFA and fibrin
sealant application. All specimens were stained with
haematoxylin and eosin, and for nicotinamide adenine
dinucleotide (NADH) diaphorase activity.
Results
The experimental procedure was performed on nine pigs
(3 pigs per Group) with a mean body weight of 85 ± 7
kg. With the exception of one pig in Group 3, all ani-
mals survived in good conditions until the day of hepa-
tectomy and euthanasia. The premature death of this
animal was in the veterinarian’s judgment caused by a
common, non-infective disease. In all nine pigs, bleeding
was stopped within 3 minutes of the application of the
fibrin sealant and no cases of recurrent bleeding were
observed. The procedure was completed in all cases and
surgical techniques to achieve haemostasis were not re-
quired. The interventions (FNA and RFA) were not asso-
ciated with complications as anticipated including
biloma, hepatic abscess, and bile duct injury. The ab-
sence of these complications typically associated with
the two interventions, was confirmed by anatomical andpathological assessments of the explanted livers. Blood
tests did not reveal any abnormal coagulation parame-
ters. The kit was easy to use and the application of the
fibrin sealant did not pose any particular technical prob-
lems. The fibrin sealant could be applied correctly: the
two sealant components were mixed correctly at 37°C
and at the proper time ensuring the optimal application
of active haemostatic agent at the treated liver sites.
Discussion
Despite considerable progress in the treatment of HCC
in situ procedures for the treatment of unresectable
hepatic malignancies are associated with serious com-
plications, including abdominal haemorrhage and bile
leakage [11,12,15,20-30]. Fibrin sealants have been used
successfully in a variety of surgical and endoscopic settings
to promote haemostasis and tissue sealing [18,19,25,31].
Even if a perfect hepatic resection has been carried out
postoperative bleeding and segregation of fluids can occur
though the resection. By using fibrin sealant the hepatic
resection area can be sealed and even the smallest micro-
lesions can be closed. In addition, the fibrin excess can
avoid early fibrinolysis. Optimal administration of the
fibrin sealant after biopsy or to the ablated site is fre-
quently difficult to achieve when the sealant is delivered
via a catheter as occurs during percutaneous procedures.
There is therefore an unmet medical need for a new deliv-
ery system that will ensure correct administration of the
effective sealant to the surgical site. Our group designed
and patented this novel dual lumen catheter system for
the infusion of bi-component haemostatic agents. The ob-
jective was to optimize administration of the fibrin sealant
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efficacy of this dual lumen catheter in an in vivo porcine
model of hepatic FNA and RFA.
The results of our small-scale trial show that the
patented minimally invasive percutaneous procedure-kit
(MIPP-Kit) confirm that the kit is significantly easier to
use in that much less force is require to push the two
substances out of the catheter and that it allows more
precise delivery of active agents to the site required.
Importantly, blockage or clogging of the catheter tip did
not occur. Investigators did not report any difficulties in
inserting the needle into the site of infusion probably as
a result of the fact that the needle was designed with an
oblique tip that facilitated easy entry.
The dual-lumen kit was also shown to be effective in
that all animals survived in good conditions until the
day of hepatectomy and euthanasia (except one non-
treatment related death). In all pigs, bleeding was
stopped within 3 minutes of the application of the fibrin
sealant and no cases of recurrent bleeding recurrence
were observed. FNA and RFA were not associated with
any complications and blood tests did not reveal any
abnormal coagulation parameters.
Conclusions
While we acknowledge that this was a small scale study
in animals, we feel confident in concluding that our pat-
ented dual lumen kit provides distinct advantages in the
administration of fibrin sealant in terms of ease-of-use
and improved delivery. The haemostatic treatment was
effective and well tolerated and both FNA and RFA pro-
cedures could be successfully and safely performed. We
look forward to the possibility of conducting larger trials
with this novel system.
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